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Abstract 
Modern synthetic organic chemistry has experienced an enormous growth in biocatalytic 
methodologies; enzymatic transformations and whole cell bioconversions have become generally 
accepted synthetic tools for asymmetric synthesis. This review details an overview of the latest 
achievements in biocatalytic methodologies for the synthesis of enantiopure compounds with a 
particular focus on chemoenzymatic synthesis in non-aqueous media, immobilisation technology 
and dynamic kinetic resolution. Furthermore, recent advances in ketoreductase technology and their 
applications are also presented.  
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1. General Introduction 
 
Asymmetric synthesis is the preferential formation of one stereoisomer of a chiral target compound 
to another; when scientists at GlaxoSmithKline, AstraZeneca and Pfizer1 examined 128 syntheses 
from their companies, they found as many as half of the drug compounds made by their process 
research and development groups are not only chiral but also contain an average of two chiral 
centres each.2 In 2006 just 25 % were derived from the chiral pool and over 50 % employed chiral 
technologies.1 In order to meet regulatory requirements enantiomeric purities of 99.5 % were 
deemed necessary by the FDA.3 This is one of the biggest challenges which face chemists today, 
primarily due to the recognition of the fact that different enantiomers of the same compound can 
interact differently in biological systems. As a consequence, the production of single enantiomers 
instead of racemic mixtures has become an important process in the pharmaceutical and 
agrochemical industry. Several routes can lead to the desired enantiomer including transition metal-
,
4-6
 organo-5,7-10 and bio-catalysis11-15 and these have been thoroughly reviewed in the literature.16,17  
 
2. Biocatalysis 
 
2.1.  Introduction 
Biocatalysis involves the use of enzymes or whole cells (containing the desired enzyme or enzyme 
system) as catalysts for chemical reactions. A timeline of historic events in biocatalysis and 
biotechnology is outlined in Table 1.18-20  
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Table 1. Historical perspective of biocatalysis and biotechnology (adapted from ref. 11) 
Years Who? Where? What? 
B.C. Unknown Old World Chymosin from calf and sheep stomach 
employed in the production of cheese 
1783–
1836 Spallanzani -
a
 
verifies in vitro “digestion” of meat in 
stomach juice: factor called “pepsin” 
1876 Kühne -a term “enzyme” for catalysts not bound to living cells 
1877 Eduard Buchner Berlin Agricultural College, Germany 
First alcoholic respiration with cell-free 
extract: vital force, vis vitalis, does not 
exist (Nobel prize 1907) 
1893 Wilhelm Ostwald Leipzig Univ., Germany 
definition of term “catalyst”  
(Nobel prize 1909) 
1894 Emil Fischer Berlin Univ.,Germany “lock and key” analogy (Nobel prize 1902) 
1903 Henry D. Dakin London, UK First enantioselective synthesis, 
with oxynitrilase 
1908 Otto Röhm Darmstadt,Germany Patent for enzymatic treatment of leather (with trypsin) 
1913-
1915 Röhm Company Darmstadt,Germany 
First laundry detergent with enzyme 
(pancreatin): “Burnus” 
1926 James B. Sumner Cornell Univ., Ithaca, NY, USA 
First enzyme crystallised: urease from jack 
beans (Nobel prize 1946) 
1936 Ernst Sym  Lipase reaction in organic solvent 
1944 Linus Pauling Caltech, Pasadena, CA, USA 
First attempt to explain enzyme catalysis 
as transition-state complementarity 
1950 Pehr Edman Univ. of Lund, Sweden Protein degradation developed 
1951 Frederick Sanger 
and Hans Tuppy 
Univ. Of Cambridge, 
UK 
Sequence determination of insulin β-chain: 
each protein is characterised by a sequence 
(Nobel prize 1978) 
1960 -a Novo (Bagsvaerd, Denmark) 
Large-scale protease production from 
Bacillus licheniformis in submerged 
culture 
1963 Stanford Moore 
and William Stein 
Rockfeller Univ., NY, 
USA 
Amino acid sequence of lysozyme and 
ribonuclease elucidated (Nobel prize 1972) 
1978 Stanley Cohen and Herbert Boyer Stanford, CA, USA 
Method of recombination of DNA 
developed 
1985 Michael Smith Univ. of British Columbia, Canada 
Site-directed gene mutagenesis to change 
enzyme sequence  (Nobel prize 1993) 
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Table 1. Continued 
Years Who? Where? What? 
1988 Kary B. Mullis Cetus Corp., CA, USA 
Invention of PCR (Nobel prize and Japan Prize 
1993) 
2000 Celera Genomics Gaithersburg, MD, USA 
Sequencing of human genome announced (3 
billion basepairs) 
aNot described. 
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Figure 1. Adapted from ref. 25. 
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Novel methodologies for discovering industrial enzymes based on genomic sequencing and 
phage display (discussed further in Section 1.3),21,22 as well as highly effective optimisation tools 
based on chemical, physical and molecular biology approaches,23 have improved the access to 
biocatalysts, increased their stability, and radically broadened their specificity.24 This greater 
availability of catalysts with superior qualities including the use of new bioengineering tools 
contributed significantly to the development of new industrial processes. Biocatalytic 
methodologies for organic synthesis were outlined by Woodley et al. in three categories: 
established, emerging and expanding chemistries as depicted in Figure 1.25 
 
2.2. Enzyme classes  
By the late 1950s it had become evident that the nomenclature of enzymes without any guiding 
authority, in a period when the number of known enzymes was increasing rapidly, led to a lack of 
clarity. The naming of enzymes by individual workers had proved inefficient; the same enzymes 
became known by several different names, while conversely the same name was sometimes given to 
different enzymes. Many of the names conveyed no information of the nature of the reactions 
catalysed, and similar names were sometimes given to enzymes of different types. The International 
Commission on Enzymes was established in 1956 by the President of the International Union of 
Biochemistry in order to resolve the issue of nomenclature.26 The EC classification system is 
derived from the biochemical function of enzymes in living systems. Every enzyme is given four 
numbers after the abbreviation EC. The first number describes the reaction type (only six are 
possible), the second number defines the structural changes which occur during the enzyme 
catalysis; the third number outlines particular enzyme characteristics involved in the catalytic 
reaction and the fourth number is a running number. This classification now contains over 3000 
entries (Table 2).13,19,27  
 
Table 2. Summary of enzyme classes (adapted from ref. 13) 
Enzyme Examples Reaction catalysed 
Hydrolases Lipase, protease, esterase, nitrilase, nitrile 
hydratase, glycosidase, phosphatase 
Hydrolysis reaction in water 
Oxidoreductases Dehydrogenase, oxidase, oxygenase, 
peroxidase 
Oxidation or reduction 
Transferases Transaminase, glycosyltransferase, 
transaldolase 
Transfer of a group from one 
molecule to another 
Lyases Decarboxylase, dehydratase, deoxyribose-
phosphate aldolase 
Non-hydrolytic bond cleavage 
Isomerases Racemase, mutase Intramolecular rearrangement 
Ligases DNA ligase Bond formation requiring 
triphosphate 
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2.3. Advantages and disadvantages of biocatalysis 
Enzyme catalysed reactions up to the last decade had many associated advantages and 
disadvantages which are outlined in Table 3.12-14,20,28-32 Enzymatic transformations commonly 
proceed with high chemo-, regio-, and enantio-selectivity and routinely achieve enantioselectivities 
of >99% e.e.12,33-37 Furthermore, the introduction of the Pollution Prevention Act of 199038 has led 
to an increased focus on green chemistry. Biocatalysis is compliant with the 12 principles of green 
chemistry;38,39 the reactions are inherently benign as they are run at low or moderate temperatures. 
Apart from high selectivity, the major advantage is that enzyme-catalysed reactions usually display 
characteristically high turnover numbers, with rate accelerations approaching or exceeding 108.  
 
Table 3. Characteristics of biocatalysis 
Advantages Disadvantages 
High substrate, regio- and stereo-selectivity 
Benign reaction conditions 
Non-toxic 
Recycling is sometimes possible 
Biodegradable waste 
Large rate enhancements 
Limited substrate specificity 
Limited enzyme availability 
Poor catalyst stability 
Require co-substrates and/or cofactors 
Inactivation may occur: 
• at high temperatures 
• at extremes of pH 
• in organic solvents 
• through product inhibition 
 
Considering that catalysis is normally carried out at ambient temperatures and pressures, the 
catalytic power of enzymes is remarkable. An example of the catalytic potential and the low cost 
application of biocatalysis is the commercial production of L-aspartic acid, an important 
intermediate of the commercially important artificial sweetener Aspartame®. Thus, 1 kg of 
immobilised aspartate ammonia lyase produces more than 100,000 kg of product 1 (Scheme 1).40,41  
 
 
                                                              1 
 
Scheme 1 
 
The principal disadvantages associated with biocatalysis, from a synthetic perspective, are that 
enzymes are sensitive, unstable compounds which can be destroyed by extreme reaction conditions 
and tend to have a limited substrate scope in many instances. They generally function well only at 
physiological pH values in very dilute solutions of the substrate. Enzymes are expensive and 
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difficult to obtain in pure form. Enzymes have also been reported to possess limited substrate scope. 
However, in the last 20 years the majority of these disadvantages have been overcome.  
 
 
3. Biocatalysis in Non-Aqueous Media 
 
A major advantage of biocatalysis is the use of water as a reaction medium owing to the low costs 
and waste associated with these environmentally friendly processes. Water is non-toxic, non-
flammable, odourless and colourless, widely available and inexpensive and is well suited for 
biphasic catalysis. However, in some instances use of water as solvent is also a chief limitation of 
biocatalysis as many of the biocatalytic substrates are poorly water soluble and product extraction 
may prove difficult e.g. dehydration reactions such as esterifications do not proceed in an aqueous 
medium. Side reactions such as hydrolysis, polymerisation or racemisation can occur leading to 
product mixtures. In some instances these challenges can be circumvented through use of 
alternative solvents, organic solvents, supercritical fluids and ionic liquids. 
 
3.1. Organic solvents 
In principle, most of the problems associated with enzymes in an aqueous environment might be 
overcome by switching from an aqueous medium to an organic solvent. Replacement of an aqueous 
medium with an organic medium would seem challenging in the light of the conventional view that 
enzymes (and other proteins) are denatured (lose their native structure and thus catalytic activity) in 
organic solvents;42 this assumption is derived from the examination of enzymes in aqueous-organic 
mixtures, not in neat organic solvent and has now been proven incorrect.43,44  
 
Table 4. Benefits of biocatalysis in non-aqueous media 
 
Although in aqueous-organic mixtures, protein molecules have both a propensity to denature 
and sufficient conformational flexibility to do so, in anhydrous solvents, due to their structural 
rigidity, denaturation is less likely.44 As a result, various crystalline enzymes essentially retain their 
native structures even in anhydrous organic solvents.45 Furthermore, protein stability is lower in 
increased substrate solubility50 
the kinetics of the reaction can be improved i.e. in extractive bioconversions the product can 
be extracted into the organic phase thereby shifting the equilibrium in favour of product 
formation51  
high yields are often associated with the introduction of organic solvents as their use can 
eradicate product inhibition and prevent the possibility of unwanted side reactions and 
improve the relative ease of product and biocatalyst recovery52 
the regio- and chemo-selectivity of enzymes can be controlled by solvent. Conversely, the 
use of enzymes in non-aqueous media can lead to protein precipitation, denaturation, a 
reduction in catalytic activity,53 stability54,55 and a change or loss of substrate specificity  
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water-miscible solvents (−2.5 < log P < 0), such as acetone, due to their ability to remove enzyme 
bound water,46-48 than in hydrophobic solvents (2 < log P < 4), such as alkanes, as they leave the 
water layer bound to the enzyme intact.49 The introduction of an organic solvent has several benefits 
as described in Table 4.  
Studies over the past 15 years have established firmly that many enzymes can work in organic 
solvents containing little or no water and the employment of organic solvents as a reaction medium 
has been reviewed in detail.52,56,57 Biocatalytic solvent systems commonly include monophasic 
aqueous-organic mixtures, biphasic aqueous-organic mixtures and enzymes suspended in pure 
organic solvents. In a biphasic system (Figure 2a), the enzyme is in a hydrophilic state present in the 
aqueous phase while the hydrophobic compounds are typically in the organic phase. In reverse 
micellar systems, the enzymes are solubilised in surfactants to form a hydrated reverse micelle 
(Figure 2b) in an organic solvent. In organic solvent systems (Figure 2c), the enzyme, either 
lyophilised or on an inert solid support, is suspended in an organic solvent system; aqueous buffer 
(<5 %) may also be present to maintain enzyme activity.  
 
         a) Biphasic system         b) Reverse micellar system           c) Organic solvent system 
 
 
 
 
 
 
Figure 2 
 
Several industrial syntheses now employ enzyme-catalysed reactions in organic media for the 
large-scale production of active pharmaceutical ingredients. For instance, Schering-Plough 
synthesise an azole antifungal agent 2 in hundred-kilogram quantities whereby the pivotal synthetic 
step is an enzymatic desymmetrisation of a symmetrical diol 3 by Novozym 435® with vinyl acetate 
as acyl donor and acetonitrile as solvent to give the monoester 4 in high enantiopurity. Acetonitrile 
was chosen as solvent as the subsequent iodocyclisation to 5 is carried out in acetonitrile and by 
simple filtration of the enzyme beads the reaction sequence was telescoped into a single step 
(Scheme 2).58 Bristol-Myers Squibb pharmaceutical research group have published a number of 
plant scale chemoenzymatic syntheses performed in organic media; some examples are depicted in 
Scheme 2.59,60  
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Scheme 2 
 
A further example which demonstrates the advantages of biotransformation in organic media is 
the synthesis of enantiopure 2-chloro- and 2-bromo-propionic acids, used as intermediates for the 
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synthesis of phenoxy propionic herbicides and some pharmaceuticals.61 These valuable chiral 
building blocks have been obtained from lipase catalysed enantioselective butanolysis in anhydrous 
solvents. Not only is this process, scaled up by Chemie Linz AG of Austria to a multikilogram 
level, thermodynamically impractical in water, but water also hinders the resolution by promoting 
racemisation.62 Although the practical utility of enzymatic catalysis in organic solvents is beyond 
doubt, most of the work so far has involved relatively simple, hydrolytic enzymes.45,63 Use of more 
complex enzymes, including those that require cofactors and especially oxidoreductases and lyases 
in organic solvents, is reported using organic solvent as a co-solvent,64-66 but, rarely in a neat 
organic solvent system.67-71 
 
3.2. Supercritical fluids  
In recent years enzyme catalysed processes have been explored in novel media such as supercritical 
fluids and ionic liquids. A supercritical fluid (SCF) is defined as the physical state of a compound or 
element above its critical temperature and critical pressure but below the pressure required to 
condense it to a solid.72,73  
 
 
 
 
Figure 3. Reproduced from ref. 73. 
 
The phase diagram for supercritical fluids in Figure 3 describes the phase behaviour of 
substances; the critical point is the point at which the densities of the liquid and gas become 
identical and fluid is said to be supercritical. The critical parameters of the primary solvents 
employed in biocatalysis are outlined in Table 5.11 Due to the temperature-sensitive nature of 
biocatalysts, a narrow range of supercritical fluids are investigated. The vast majority of research 
has employed the use of supercritical carbon dioxide (scCO2), as it is inexpensive, benign, readily 
available, and has low toxicity and its relatively low supercritical parameters facilitate its use as a 
solvent for biocatalysis.74-76 Other supercritical fluids including freons (CHF3),77 hydrocarbons 
(ethane, ethene and propane)78 or inorganic compounds (SF6, N2O)79 have also been reported as 
media for biocatalysis.  
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Table 5. Critical parameters of solvents employed in biocatalysis (adapted from ref. 11) 
Fluid Tc (ºC) Pc (bar) δc (g/mL) 
Ethylene 9.5 50.8 0.22 
CHF3 25.9 46.9 0.52 
CO2 31.3 73.8 0.47 
Ethene 32.3 48.8 0.20 
SF6 45.5 37.1 0.74 
Propane 96.6 42.5 0.22 
Butane 152.0 37.5 0.27 
 
The field of investigations of enzyme catalysis in scCO2 has been continuously growing since 
the mid-1980s, when Randolph et al. were the first to conduct an enzymatic reaction in scCO2 using 
alkaline phosphatase (Scheme 3).80  
 
 
 
Scheme 3 
 
Several reviews on enzymatic catalysis in supercritical fluids are available.72,78,81-84 The chief 
advantage of SCFs is the tunability of the properties of the solvent, through slight changes of the 
pressure and/or temperature. It is well established that success of biocatalysis (i.e. enzyme activity, 
specificity and enantioselectivity) in conventional solvents, is susceptible to solvent properties 
including dielectric constant, partition coefficient and hydrophobicity.85-91 Therefore, it is not an 
unexpected result that changes in the properties of SCFs dramatically affect enzyme activity.  
A number of hydrolase-mediated resolutions have been performed in scCO2, in a number of 
cases the enantioselectivity could be controlled by variation of reaction parameters.63,64,92 For 
example when the enantioselectivity of lipase-catalysed esterification of 1-(p-chlorophenyl)-2,2,2-
trifluoroethanol 6 was examined in scCO2 the E-value of 7 changed continuously from E=10 to >60 
by altering the temperature and pressure. The enantioselectivity of the reaction was higher at low 
pressure and low temperature (Figure 4).93 
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Temperature 
(°C) 
Pressure 
(mPa) E-value 
31 17 38 
31 8 60 
40 13 24 
40 8 65 
60 21 10 
60 9 40 
 
Figure 4. Effect of pressure on enantioselectivity of acetylation of (±)-6 in supercritical carbon 
dioxide catalyzed by lipase Novozym at 31 °C, 40 °C  and 60 °C.94 
 
Palocci et al. have described how scCO2 can modulate regioselectivity in the acylation of 6-O-
trityl-β-D-glucopyranoside 8 by using lipase from Candida rugosa. The regioselectivity of the 
reaction was shifted towards the synthesis of 3-O-acetyl-6-O-trityl-β-D-glucopyranoside 9, with 
variation of the physicochemical parameters of scCO2, formation of a single regioisomer (9) could 
be effected in 91% yield (Scheme 4).95 
 
 
 
Scheme 4 
 
In scCO2, improved enantioselectivity of transesterification reactions has been attributed to the 
covalent modification of enzymes by reaction with CO2.96 High pressures (>400 MPa) can lead to 
irreversible structural changes in the enzyme, but within a pressure range of 10–40 MPa only 
reversible changes can occur.96 A high temperature is always destructive especially over long 
periods of time.96 Another critical parameter to enzyme activity in supercritical fluids is water 
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content. The presence of some water is required as enzymes require a specific amount of water 
bound to them to maintain activity. A very low water content is required for enzyme activity in 
SCF-mediated reaction systems e.g. Novozym (<0.05% v/v),97,98 lipase IM-20 (5% v/v).99 
Reductions in reaction rate were found with increasing hydrophobicity of solvents.82 
The principal drawback to the use of SCFs is the requirement of specialised equipment that can 
withstand high pressures which has an associated increase in cost on plant scale. Adverse effects on 
enzymes have also been documented, scCO2 has been reported to form carbamates (Scheme 5) 
between CO2 and the amine groups on lysine residues, or potentially the imidazole side chain of 
histidine on the enzyme surface, which can lead to enzyme deactivation.100-102 In contrast, some 
reports detail enhanced stereoselectivity which has been attributed to carbamate formation.103 A 
further complication associated with the use of scCO2 is the formation of carbonic acid (Scheme 5), 
which results in a lowering of the pH of water in the microenvironment of the enzyme which can 
result in a change in enzyme activity.104  
 
 
 
Scheme 5 
 
Another major drawback of scCO2 is the fact that it exhibits very low solubilities for polar 
and ionic substances. In order to overcome this limitation, the use of microemulsions with special 
CO2-philic surfactants has attracted attention. Microemulsions in scCO2 allow one to dissolve 
hydrophilic substances such as proteins within the aqueous core of the microemulsion 
nanodroplets.80,105 Moreover, they can be applied for the preparation of nanoparticles of defined 
size. Recently, enzymatic reactions in microemulsions in scCO2 have been reported in literature.106-
108
  
 
3.3. Ionic liquids 
The employment of ionic liquids (ILs) for biocatalytic reactions has received a lot of attention in the 
literature in the last decade and has been recently reviewed in great detail.109-118 Ionic liquids are 
organic salts which are liquids at room temperature. Ionic liquids possess unique properties; they 
are not volatile or flammable and possess excellent chemical and thermal stability,119 furthermore, 
they have been described as environmentally benign120 which make them an attractive alternative to 
traditional organic solvents. Ionic liquids possess many attractive properties, these include 
negligible vapour pressure,116 high polarity due to multiple ionic interactions with organic and 
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inorganic compounds121 and most importantly the properties of ionic liquids such as the viscosity, 
hydrophobicity, density and solubility are tunable by simply varying the combination of cations and 
anions (Table 6).  
 
Table 6. Typical structures of ionic liquids commonly used for biocatalysts 
Cations Anions 
N N
R1 R2
N
R1 R2
N
R2R4
R3
R1
NR1 R2
1, 3-Dialkylimidazolium (Im)
1, 3-Dialkylpyridinium (Py)
Tetraalkylammonium
 ,-Dialkylpyrrolidinium (Py)
N
R2R4
R3
R1
Tetraalkylphosphonium
 
Anion Full Name Abbreviation 
BF4- Tetrafluoroborate [BF4] 
PF6- Hexafluorophosphate [PF6] 
NO3- Nitrate [NO3] 
CH3CO2- Acetate [Ac] 
CF3CO2- Trifluoroacetate [Tfa] 
CH3OSO3- Methyl sulfate [MeSO4] 
CF3SO3- 
Trifluoromethane-
sulfonate [TfO] 
(CF3SO2)2N- Bis(trifluoromethyl)-
sulfonimide [Tf2N] 
 
The first report on the employment of ionic liquids as solvent in the production of Z-aspartame 
by thermolysin as catalyst was in 2000 by Russell et al. (Scheme 6).122 Since this initial publication 
a wide range of enzymatic transformations have been investigated in ionic liquids e.g. lipases,123-132 
proteases,133-135 oxidoreductases,136-138 cytochrome p450,139 peroxidase,140-146 hydroxynitrile lyase147 
and alcohol dehydrogenases.118,148 Ionic liquids have been reported to improve activity,149-153 
selectivity149,150,154-156 and the stability of enzymes.116,149,157,158  
Biocatalytic redox reactions are often performed using whole cell biocatalysts, as the cells 
contain the recycling redox cofactors, and, are less susceptible to denaturation than isolated 
enzymes. It has been demonstrated that use of organic solvents can be replaced by an ionic liquid 
which seems to be less harmful to the cell membranes.159 For instance, a range of ketones were 
reduced enantioselectively to the corresponding (S)-alcohols by an immobilised yeast in 
[BmIm][PF6]-water (90 : 10) biphasic medium. On average the performance was on a par with that 
in an organic medium (Scheme 7).160 With isolated enzymes excellent enantioselectivity was 
achieved in all cases (Scheme 7).161 
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Scheme 6 
 
 
 
  
 
Scheme 7 
Reviews and Accounts  ARKIVOC 2012 (i) 321-382 
Page 336 ©ARKAT-USA, Inc. 
Drawbacks of ionic liquids are that they are relatively expensive, and have been associated with 
difficult product separations. Critically, many ILs are as, or more, toxic than the organic solvents 
they are replacing. They have been reported to possess antibacterial activity, cytoxicity and toxicity 
towards multicellular organisms,162 and ecotoxicity in the case of aquatic organisms and terrestrial 
plants.163,164  
 
3.4. Novel application of fluorous solvents in product isolation following biocatalysis 
An interesting application of solvents for biocatalysis was developed in 2002 by Theil et al.165-167 
Initially lipase-mediated kinetic resolution of a range of alcohols with fluorous esters was 
performed and repeated washing with the fluorous solvent removed the transformed ester in high 
enantiopurity with the untransformed alcohol remaining in the organic phase also in excellent 
enantiopurity.165 This methodology was adapted to lipase-mediated hydrolysis of highly fluorinated 
esters with similar results.166,167  
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Figure 5. Adapted from ref. 167. 
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Combination of the kinetic resolution by enzymatic deacylation with fluorous triphasic reaction 
and subsequent separation yielded the enantiomeric alcohols in excellent enantiopurities and good 
yields (Figure 5). The racemic ester is initially enzymatically resolved with Candida antarctica B 
and the mixture filtered and added to the source phase which consists of a methanol/chloroform 
mixture, FC-72 consists of perfluorohexanes which acts as the separation medium. The 
untransformed alcohol remains in the source phase while the fluorinated ester diffuses to the 
receiving phase which subsequently hydrolyses to the desired opposite enantiomer. The cleaved 
fluorous moiety mainly remains in the fluorous phase.167 This innovative example illustrates the 
potential for exploring differential solubility as a product isolation technique. 
 
 
4. Enzyme Immobilisation 
 
4.1. Introduction 
Immobilisation typically involves attachment or dispersion of an enzyme or cell to an insoluble 
support material to create a heterogeneous system. The principal types of immobilisation are 
outlined in Figure 6.168 
 
 a)                                    b)                                c)                                 d) 
                                                                                                           
 
 
 
 
 
 
Figure 6. Enzyme immobilisation strategies: (a) entrapment, (b) encapsulation, (c) solid support, 
(d) enzyme crosslinking (adapted from ref. 168). 
 
The employment of enzyme immobilisation technology has gained momentum in the last 
decades for several reasons. The principal advantages of immobilisation are that it allows facile 
recycling and repeated reuse of the biocatalyst in batch operations which significantly improves the 
commercial viability of enzyme-mediated processes. Immobilisation also facilitates the recovery 
and reuse of costly enzymes, facile handling of the enzyme and easier product recovery. Other 
advantages associated with enzyme immobilisation are improved enzyme performance, and 
increased pH and temperature stability.168-170 Biocatalysis in organic media is associated with the 
formation of enzyme aggregates, which can lead to poor accessibility of the substrate. Enzyme 
immobilisation has been reported to significantly increase (several hundred fold) enzyme activity in 
organic solvents.49,170,171 Furthermore, enhanced activity of immobilised lipases has been reported, 
this hyperactivity has been attributed to the lipase being trapped in its open more active 
conformation during the immobilisation process.170,172-175 Furthermore, modification of enzyme 
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substrate selectivity has been reported by direct immobilisation through attachment of a support to a 
specific site on the enzyme which can lead to changes in enzyme structure and thus function.176 
Comparison of the various immobilisation methods has received a lot of attention and they have 
been reviewed in detail.168-170 
 
4.2. Cross-linked enzyme aggregates 
In recent years, carrier-bound cross-linked enzyme aggregates (CLEAs) have attracted increasing 
attention, due to their simplicity, broad applicability, high stability, and high volume activity. 
Studies in the early 1960s led to the discovery that cross-linking of dissolved enzymes via reaction 
of surface amino groups with a chemical cross-linker such as glutardialdehyde resulted in the 
formation of insoluble cross-linked enzymes.177 Carrier-free immobilised enzymes are generally 
prepared by cross-linking enzyme preparations such as crystalline, spray-dried, dissolved or 
physically aggregated enzymes, resulting in the formation of cross-linked enzymes. The different 
approaches to carrier-free immobilised enzymes are illustrated in Figure 7.169  
 
(CRY) crystals                                                                                            a) crystallisation 
(AGG) aggregates                                                                                      b) aggregation 
(SDE) spray-dried enzyme                                                                     c) spray-drying 
                                                                                                      d)  direct-crosslinking  
 
Figure 7. Formation of a cross-linked enzyme crystal (CLEC), a cross-linked enzyme aggregate 
(CLEA), a cross-linked spray-dried enzyme and a cross-linked dissolved enzyme (CLE), adapted 
from ref. 169. 
  
CLEAs have received increasing attention in recent years due to their facile preparation and as a 
cheaper alternative to expensive supports;170 they achieve higher volumetric activities (10-1000 U/g 
time higher) than carrier bound enzymes.178 The most efficient of the CLEA methods is the physical 
aggregation of enzymes followed by chemical crosslinking.179 Enzymes which have been 
successfully immobilised using cross-linking enzyme methodology include horseradish 
peroxidase,180 lipases,181-185 nitrilase,186  and esterases.187  
 
Dissolved Enzyme
(a)
(b) (c) (d)
Cross-linker
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4.3. Practical applications of cross-linked enzyme aggregates  
One example which demonstrates the aforementioned advantages of immobilisation is the 
immobilisation of oxynitrilases. (R)-Oxynitrilases catalyse the hydrocyanation of aldehydes to form 
a wide range of (R)-cyanohydrins with high enantioselectivity.188-190 These reactions are typically 
performed in an aqueous organic two-phase system, in which the enzyme resides in the aqueous 
phase and the reactants and products are dissolved in the organic phase. The resulting low reactant 
concentration in the aqueous phase suppresses the un-catalysed background reaction that otherwise 
would decrease the enantiopurity of the products.188-190 Free (R)-oxynitrilases suffer from rapid 
deactivation, low substrate loading and poor recyclability.188,190 
 
 
 
Figure 8. Adapted from ref. 191. 
 
As is evident from Table 7 by modifying the enzyme through cross-linking and entrapping 
(Figure 8)191 an improved result was obtained, regarding efficiency as well as yield and 
enantioselectivity. The desired (R)-mandelonitrile 11 was obtained with 94% e.e. and 93% yield 
(Table 7, entry 2).190 Furthermore, even after reusing the lens-shaped catalysts 20 times, no decrease 
in conversion was observed. In contrast, the e.e. slightly increased from 91% e.e. to 95% e.e. This 
might be due to an increased stabilisation of the enzyme within the hydrogel matrix.190-191 A further 
example of the synthetic utility of CLEAs is demonstrated by Cao et al.192 Penicillin G acylase is 
widely used in the industrial synthesis of Ampicillin 12. All viable syntheses involve an activated 
side-chain donor such as D-phenylglycine amide 13 which acylates 6-APA 14 in the presence of 
penicillin acylase in a kinetically controlled reaction; water is the reaction medium of choice.  
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Table 7. Entrapped biocatalysts in asymmetric hydrocyanation 
 
 
 
Entry Type of oxynitrilase U per mmol Organic solvent Yield ( %) 
e.e. 
( %) 
1 free 15 MTBE/hex 85 95 
2 Entrapped (8) 15 MTBE/hex 93 94 
3 Entrapped (40) 150  MTBE/hex 74 91 
4 Entrapped (40) 75 EtOAc 62 93 
5 Entrapped (40) 75 MTBE/ 70 92 
6 Entrapped (40) 100 i-Pr2O 84 99 
 
Table 8. Ampicillin synthesis catalysed by different Penicillin G Acylase preparations192 
 
 
 
Biocatalyst Conversion (%) Relative productivity 
Free enzyme 88 100 
CLEC 72 39 
T-CLEA 85 151 
PGA-450 86 0.8 
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Table 9.  Synthesis of Ampicillin 12 catalysed by T-CLEA in organic solvents192 
Solvent Log P Conversion 
Triglyme −1.8 5 
2-Methoxyethyl ether −1.3 11 
1,2-Dimethoxyethane −0.8 10 
Acetonitrile −0.4 17 
2-Ethoxyethyl ether −0.3 25 
2,2-Dimethoxypropane −0.2 56 
tert-Butyl alcohol 0.8 18 
tert-Amyl alcohol 1.4 33 
 
A major problem of such schemes is the competing irreversible hydrolysis of the acyl donor as 
well as the product.193 A simple solution would be to perform the reaction in an organic medium, 
however, the free enzyme is known to have a limited thermal stability and a very low tolerance 
toward organic solvents.192 As is evident from Table 8, immobilisation by CLEA  improved the 
activity when compared to the free enzyme.192 Free penicillin G acylase is readily and irreversibly 
deactivated by organic solvents. However, as is apparent from Table 9 immobilised penicillin 
acylase is active in the synthesis of ampicillin in a broad range of organic solvents; no correlation 
between log P and conversion was observed.192,194,195 
 
 
5. Genetic Engineering of Enzymes 
 
Enzymes have evolved over millions of years to react in a physiological environment, on a narrow 
range of natural substrates and typically at low concentrations. However, particularly on an 
industrial scale, biocatalysts are required to operate on a range of non-natural substrates and in 
difficult reactions conditions i.e. extremes of temperature, pH, concentration and pressure with 
repeated and prolonged use. Furthermore, they need to perform in non-aqueous solvents in order to 
facilitate substrate solubility and/or product extraction. It is not surprising that the majority of 
natural enzymes do not meet these requirements. Modification of the enzyme is required to provide 
the necessary stability and activity. Use of chemical and/or physical enzyme engineering techniques 
is one solution (Section 1.4). However, enzyme engineering requires the enzyme to already possess 
relatively high substrate selectivity, and, is somewhat limited in the improvements it can make. 
Genetic engineering of the enzyme is required to alter the stereoselectivity, substrate scope and/or 
improve the enzyme activity. The early 1990s saw the development of new approaches to the 
enzyme optimisation technologies methods with the emergence of gene library generation via DNA 
shuffling196,197 and PCR techniques.198 Two principal processes routinely used to achieve this are 
rational design and directed evolution.  
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5.1. Rational design and directed evolution 
An overview of rational design is depicted in Figure 9;199 in rational protein design, mutants are 
planned on the basis of their protein structure. They are prepared by site directed mutagenesis. 
Following transformation into the host expressing organism e.g. E. coli, the variantis expressed, 
purified and analysed for the desired traits.  
Comprehensive overviews of the influence of rational design on protein activity are 
available.200-202 Some specific examples include the employment of rational design to increase the 
stability of enzymes by the introduction of proline residues,203,204 disulfide bonds,205 or mutation 
towards the consensus for a given enzyme family.206,207 Rational design has also been employed to 
alter cofactor specificity208-211 and modify enzyme specificity by a redesign of the substrate binding 
site,212-215 or changing the position of a charged residue to favour transformation of one substrate 
over another.216,217 Unlike directed evolution, improvements or inversion of enantioselectivity are 
rarely reported by groups examining protein engineering through rational design. 
Directed evolution is employed to improve the stability and enzymatic function of proteins by 
repeated rounds of mutations and selection and this method has been thoroughly reviewed in the 
literature.218-222 Directed evolution commences with a parent protein and an engineering goal such 
as enhanced selectivity or protein stability on a particular substrate. The parent gene is subjected to 
a number of random point mutations to produce a library of mutants. Proteins encoded by these 
mutant genes are then produced and screened for the desired function and the proteins are used as 
the parents for another round (Figure 9). The beneficial mutations are collected until the desired 
outcome is achieved or no other improvements are practically feasible. This methodology requires 
careful experimental design, for a protein that is composed of 350 amino acids, 20,400 possible 
sequences exist. A single mutation of an amino acid would lead to 7,600 variants, a double mutation 
would lead to 144,000 variants. Initially scientists attempted to develop a screening protocol for the 
result of each mutation, however, it was clear this was not possible. Codexis tried to tackle this 
issue with the development of an algorithm named Pro-SAR (protein sequence activity relationship) 
whereby all mutations were assigned either beneficial, neutral or deleterious properties based on the 
function for which they were being designed. Another approach to reduce the vast array of possible 
mutation was to only perform mutations at the enzyme active site.  
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Figure 9. Reproduced from ref. 199. 
 
 
5.2. Practical applications of genetically modified enzymes 
Directed evolution has been utilised to significantly improve the enantioselectivity (Figure 10, 
example A and B), catalytic activity (Figure 10, example B) and substrate concentration (Figure 10, 
example C) of a number of enzymes; inversion of enantioselectivity has also been obtained by 
directed evolution (Figure 10, example D). Examples of each of these are described in Figure 10. 
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Scheme 8 
 
An excellent example of the application of molecular modelling, and how a small change in the 
genetic sequence of an enzyme can dramatically affect the activity of an enzyme was demonstrated 
by Roticci et al.240 It was shown that the enantioselectivity of Candida antarctica B lipase-catalysed 
resolution of 1-chloro-2-oktanol was improved from E = 14 to 28 by a single amino acid exchange 
as predicted by molecular modelling.240  
 
 
6. Kinetic and Dynamic Kinetic Resolution-a Biocatalytic Perspective 
 
Despite the impressive progress in asymmetric synthesis, the resolution of racemates is one of the 
main methods to obtain a single enantiomer.16,17 The resolution of enantiomers has been performed 
by preferential crystallisation,241-245 diastereomer crystallisation,245-247 kinetic and dynamic kinetic 
resolutions. For both reaction types, kinetic and dynamic kinetic resolution, a basic criterion has to 
be fulfilled; thus, in order to obtain any resolution at all, the reaction rate (Figure 12) of one 
enantiomer has to be much faster than that of the other, i.e. kFast>kSlow.248,249 A common example of 
kinetic resolution is the reaction of a racemic alcohol with an acyl donor in the presence of an 
enzyme. The resolution of racemates employing enzymatic means has become an important tool for 
resolving enantiomers achieving enantiopure biologically active compounds.11-15 
 
6.1. Kinetic resolution 
Kinetic resolution is a process in which one of the enantiomers of a racemic mixture is more readily 
transformed into a product than its mirror image.250 The principal requirement of this process is that 
the rate of transformation of the R enantiomer is not equal to the rate of transformation of the S 
enantiomer (Figure 11).  
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(S)-substrate
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(S)-substrate
Kinetic resolution
KR
KS
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Figure 11 
  
In enzymatic kinetic resolution a racemic substrate undergoes an enzymatic resolution process 
wherein chiral discrimination of enantiomers takes place. In an ideal enzymatic kinetic resolution 
process a maximum yield of 50% can be achieved which is a severe limitation of this protocol. 
Thus, the resolution is usually accompanied by additional processing such as separation, 
racemisation and recycling of unwanted enantiomers which can contribute to high processing costs. 
A vast array of examples of enzymatic kinetic resolution are available in the literature and these 
have been reviewed in detail.251-253 Figure 12 describes examples of enzymatic kinetic resolution of 
an achiral substrate by acylation, deacylation, oxidation, and reduction.   
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6.2. Dynamic kinetic resolution 
When a kinetic resolution process is accompanied by racemisation of the substrate this is termed 
dynamic kinetic resolution (DKR). The driving force for a dynamic kinetic resolution process is that 
there is an increase in entropy when two enantiomers are mixed.259 Therefore, the following 
elements are required in order for an efficient dynamic kinetic resolution process to occur: the 
kinetic resolution step has to be irreversible, the E-value has to be at least 30, preferably between 50 
and 100, and the rate of racemisation has to be greater than the rate of reaction of the slow reacting 
enantiomer. In situ racemisation of the slow-reacting enantiomer leads to deracemisation by 
dynamic kinetic resolution and makes a theoretical yield of 100% possible (Figure 13). This makes 
DKR an attractive method to gain access to a desired enantiomer in high yield. Chemoenzymatic 
methods of DKR have been thoroughly reviewed.11,244,248,249,252,260-262 
 
 
 
Figure 13 
 
6.2.1. Dynamic kinetic resolution without metal catalysis. Zwanenburg et al. have classified the 
racemisation into different methods: i) thermal racemisation, ii) base-catalysed racemisation, iii) 
acid-catalysed racemisation, iv) racemisation via Schiff bases, v) enzyme-catalysed racemisation, 
vi) racemisation via redox and radical reactions.263 Base catalysed racemisation is one method of 
racemisation and it involves the removal of hydrogen from the chiral centre to form a carbanion, 
which makes chiral compounds which possess an acidic proton ideal substrates for this process. The 
resultant carbanion needs to be stabilised by an electron withdrawing group such as keto, nitro, 
nitrile (Figure 14a) or by reversible elimination of a β-substituent (Figure 14b). Oxidation and 
reduction reactions are also employed to produce racemates, oxidation removes a hydrogen from a 
chiral centre and subsequent reduction or hydrogenation will lead to racemate formation (Figure 
14c).263 
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Figure 14 
 
Lipase-mediated aminolysis has been converted to a DKR process by the incorporation of 
racemisation agents such as salicylaldehyde and pyridoxal 15 via the formation of an imine 
intermediate 16 (Scheme 9).253 Enzymatic dynamic kinetic resolution has been performed with 
thioesters due to the high acidity of their α-protons (Scheme 10).264  
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Scheme 10 
 
Heterocycles such as pyranones and pyrrolidinones have proved ideal substrates for dynamic 
kinetic resolution by enzymatic means. Racemisation occurs spontaneously due to the inherently 
labile nature of these compounds (Scheme 11).265 A similar observation was observed in the kinetic 
resolution of 8-amino-5,6,7,8-tetrahydroquinoline 17. A spontaneous DKR process was observed 
due to formation of an intermediate 18 in the reaction and reformation via an imine mechanism of 
the racemic hydroxy pyrrolone 17; moderate to good yields are reported (Scheme 11).266 
 
 
 
Scheme 11 
 
An unusual DKR process was reported by Bertrand et al. whereby an in situ free radical 
mediated racemisation of amines via an alkylsulfanyl radical was employed with lipase-mediated 
transesterification up to 81 % conversion with 99 % e.e. reported.267 Immobilised lipase-catalysed 
DKR yielding optically active cyanohydrin acetates were obtained in good yields and up to 93 % 
e.e. employing the use of a silica-supported ammonium hydroxide as the racemisation catalysts 
(Scheme 12).268 
 
 
 
Scheme 12 
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The nitroaldol product of the Henry reaction is an ideal substrate for a dynamic kinetic 
resolution process as the resultant β-nitroalcohols possess a highly acidic proton α to the nitro group 
which is easily removed by base. Vongvilai et al. through a one-pot nitroaldol reaction in the 
presence of triethylamine, acyl donor and Pseudomonas cepacia, obtained a range of nitroalcohols 
in good yields and enantioselectivities (Scheme 13).269,270 
 
 
Scheme 13 
 
Maguire et al. reported efficient spontaneous dynamic kinetic resolution of 2-
benzenesulfonylcyclopentanone and 2-benzenesulfonylcyclohexanone under Baker’s yeast 
reduction conditions both in organic and aqueous solvents to form the corresponding cycloalkanols 
in excellent enantiopurity; however, reduction of larger ring sizes was less efficient (Figure 15).271 
 
 
 
n 
% 
Conversion 
% 
e.e. 
d.r. 
1 95 >98 98:2 
2 85 >98 >98:2 
3 11 - - 
4 0 - - 
 
Figure 15 
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6.2.2 Dynamic kinetic resolution with metal catalysts. In recent years, chemoenzymatic DKR of 
secondary alcohols has been a rapidly evolving field of research. Metals such as rhodium, iridium 
and ruthenium are known to racemise secondary alcohols, for the in situ conversion of unwanted 
enantiomers to products, but only a few of these metals have proved compatible with enzymatic 
reaction conditions, and these have been reviewed.250,272-281 The first example of a chemoenzymatic 
DKR of secondary alcohols was reported by Williams; a ruthenium catalyst was combined with a 
lipase to produce enantiopure acetate of 1-phenyl ethanol in 81% conversion and 96% e.e.278 
Bäckvall made significant improvements to this procedure by using immobilised Candida antarctica 
Lipase B and a ruthenium complex. An argon atmosphere was essential for high efficiency as a 
nitrogen atmosphere led to a 36% reduction in yield but the enantioselectivity was unaffected 
(Scheme 14).282 
 
 
 
Scheme 14 
 
Since these initial reports a vast array of secondary alcohols have been examined under 
ruthenium/lipase combination DKR conditions: allylic alcohols, benzoins, diols, hydroxyaldehydes, 
hydroxyacids, 1,2-diarylethanols, γ-hydroxy amides, β-hydroxylalkyl sulfones, and these have been 
reviewed.250,272-281 It should be noted that vinyl acetate is incompatible with the ruthenium 
complexes explored, while isopropenyl acetate can be used with the majority of monomeric 
ruthenium complexes. p-Chlorophenyl acetate is the best acyl donor for the dimeric ruthenium 
complexes.283 The racemisation mechanism, of ruthenium catalysed dynamic kinetic resolution of 
secondary alcohols proposed by Bäckvall et al. is depicted in Scheme 15.284 The ruthenium halide 
complex is activated by the substitution of chloride with tert-butanol; ligand exchange with the 
substrate alcohol leads to a second alkoxide intermediate which undergoes a hydride elimination to 
give the oxidised intermediate; insertion of the ketone into the Ru-H bond produces the racemic 
alkoxide.284 
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Scheme 15 
 
Other metal/enzyme systems have provided a DKR system for the resolution of secondary 
alcohols. Aluminium is an attractive alternative to ruthenium as it is relatively cheap and widely 
available. Müller et al. examined several aluminium species and found that an AlMe3-BINOL 
complex led to racemisation of 1-phenyl ethanol in toluene at room temperature. This was 
subsequently coupled with Novozym 435® and excellent conversion and enantioselectivity was 
observed with a range of secondary alcohols.285 Vanadium has also been employed for the 
racemisation of allylic alcohols through the formation of allyl vanadate intermediates (Scheme 
16).286,287  
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Scheme 16 
 
Palladium metal has also been investigated as an amine racemisation catalyst. The first report 
described a palladium on charcoal mediated DKR with 1-phenylethylamine in triethylamine; 
reactions took 8 days at 50–55 °C, and poor yields are reported.288 Alkaline earth supports such as 
BaSO4, CaCO3, CaCO3 and SrCO3 have been employed in conjunction with palladium catalysts; 
The combination of palladium, supported on alkaline earth supports with a lipase resolves a range 
of benzylic amines as substrates to provide good conversions (up to 91 %) and enantioselectivities 
(99 % e.e) under hydrogenolysis mediated conditions.286,289 Vos et al. expanded this study by the 
use of heterogeneous Raney® nickel and cobalt catalysts and achieved both excellent conversions 
and enantiopurities.290 The racemisation methodology of amines under hydrogenation in the 
presence of metal catalysis is depicted in Scheme 17.290 
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Scheme 17 
 
Kim et al. reported the production of highly enantioenriched acetylated amines by 
lipase/palladium DKR catalysis in the presence of an acyl donor with the employment of ketoximes 
as starting materials under hydrogenation conditions (Scheme 18).291 
 
 
 
Scheme 18 
 
 
7. Baker’s Yeast Mediated Resolution of Sulfur Containing Compounds 
 
7.1. Introduction  
In 1874 the reducing action of Saccharomyces cerevisiae was first described in the literature by 
Dumas.292 Baker’s yeast was first applied industrially in 1997 in the synthesis of Trimegestone, a 
norsteroidal progestomimetic compound (Scheme 19).293  
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                                                                                     49 % yield 
                                                                                     99.5 % e.e. 
 
Scheme 19 
 
Crocq et al. chose Baker’s yeast due to its “si” selectivity in the reduction of prochiral 
ketones bearing a carbonyl function group at the α- or β-position.29,293-296 Baker’s yeast has been 
used extensively on the laboratory scale to perform reductions and has several advantages with 
regard to industrial applications: no toxicity or ecotoxicity, a consistent quality, as a result of its use 
in the baking industry, and a very low price. Another advantage of whole cell systems such as 
Baker’s yeast is that they do not need extra cofactors as they possess all the necessary enzymes for 
cofactor regeneration.11,250,295,297-299 Dehydrogenases and reductases have been found to be the key 
enzymes responsible for catalytic activity in the reduction of carbonyl groups to hydroxyl groups. 
Alcohol dehydrogenases (ADHs) are responsible for the reduction of carbonyls, while enoate 
reductases (ERs) account for the reduction of ‘activated’ carbon-carbon double bonds.297,300 
However, these enzymes require a nicotinamide cofactor, NAD(P)H, from which a hydride is 
transferred to the substrate carbonyl carbon. The oxidised form of the cofactor, NAD(P)+ is 
transformed back to its reduced form for the next cycle of the reduction process. The cofactor 
regeneration of alcohol dehydrogenase and enoate reductase in the biocatalytic reduction process 
with Baker’s yeast is illustrated in Scheme 20. The cofactor is regenerated by glucose 
dehydrogenase (GDH) which is already present in the cell, in the presence of the required co-
substrate such as glucose or ethanol.297,300 
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Scheme 20. Bioreduction of ketone and alkene groups by Baker’s yeast. 
 
The main drawback of Baker’s yeast as a chemical tool is its low productivity, thus, requiring 
large amounts of Baker’s yeast and highly dilute media. Moreover, the recovery of the product from 
the enzymatic medium can be tedious, particularly the filtration stage. Because these reactions 
require nicotinamide cofactors (NADPH), the use of whole cells rather than isolated enzymes is 
preferred, to avoid the need for enzyme purification and cofactor regeneration. Enantioselectivity is 
governed by geometry of hydride addition and refers to the configuration of the newly created 
alcohol stereocentre and generally follows Prelog’s rule with approach of the hydride from the “re” 
face of the carbonyl to give the S-enantiomer of the alcohol (Figure 16).11,250,295,297-299,301  
 
 
 
Figure 16. Baker’s yeast reduction of carbonyl compounds follows Prelog’s rule. 
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In some cases, these reductions proceed smoothly to yield a single product; however, with more 
complex substrates, mixtures of stereoisomeric alcohols can often result. The recognition that 
multiple yeast reductases with conflicting stereoselectivity are the main source of these difficulties 
has inspired a search for methods to improve the outcome of whole cell bioreductions via genetic 
engineering techniques (Section 7.3).11,295,298,299,302 A number of alternative strategies aimed at 
improving stereoselectivity of ketone reductions by whole yeast cells has also been explored, 
usually by selectively diminishing the catalytic activities of reductases that yield unwanted 
products. Thus, substrate modification,303 changes in the carbon source or growing conditions,304 
the use of inhibitors,305-307 addition of inorganic salts,308,309 thermal pre-treatment,310 and 
immobilisation of Baker’s yeast311 have been employed to improve the enantioselectivities of 
Baker’s yeast reductions.  
 
7.2. Baker’s yeast reduction of sulfur containing compounds 
Ridley and co-workers were one of the first groups to attempt Baker’s yeast reductions of sulfur-
functionalised acetone derivatives and reported that the reduction proceeded more efficiently for 
sulfoxides and sulfones than for the corresponding sulfides.312 Enzymatic enantioselective 
reductions of β-keto phenylsulfones has attracted considerable attention from synthetic chemists in 
the past few decades. The enantioenriched β-hydroxyl phenylsulfones are useful building blocks in 
natural product synthesis, as the keto group reductions proceed with very high stereoselectivity.313 
Moreover, the phenylsulfonyl group allows for further functionalisation and can easily be removed 
without any racemisation of the chiral centre.314 Simple acyclic β-keto sulfones have been reduced 
using Baker’s yeast.312,313,315,316 However, the enantioselectivity and efficiency of reduction 
decreased considerably once the alkyl chain was extended.313,317,318 Svatoŝ et al. investigated the 
reduction of γ-methyl-β-ketosulfones by 20 different yeasts and achieved 99% e.e. in the case of 
Schizosaccharomyces pombe.319 Baker’s yeast reduction of sulfur containing compounds has been 
reviewed in detail within this research group.306,307 One recent example of enzymatic reduction of β-
ketosulfones by a whole cell system is the reduction of β-ketosulfone groups bearing bulky 
substituents by the fungus Culvaria lunata with an enantiomer excess of 97%.320 Examples of 
Baker’s yeast mediated resolutions of 2-keto sulfides, sulfoxide and sulfones are depicted in Figure 
17 below. 
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Example A:321-323 Baker's yeast mediated resolution of 2-ketosulfides
Example B:307
Baker's yeast mediated resolution of 2-ketosulfoxides
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Figure 17 
 
7.3. Genetically engineered Baker’s yeast 
Sequencing of the 12,057,500 chemical subunits contained in yeast’s nuclear DNA was completed 
in 1996 following a combined initiative involving 92 laboratories worldwide.324-326 The 
identification of all 6,000 yeast genes arranged on 16 chromosomes paved the way for future 
investigations of individual gene functioning in Baker’s yeast mediated reductions and, hence, the 
rational design of engineered strains to achieve improved stereoselectivities. Later work led to the 
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division of yeast reductases into different families based on their length, consensus motifs, sequence 
identities and conserved residues.327  
 
 
Figure 18. Genetic engineering strategies for Baker’s yeast (reproduced from ref. 333). 
 
Two main yeast protein superfamilies capable of oxidoreduction of endogenous and xenobiotic 
carbonyls have been identified; namely the aldo-keto reductase (AKR) and short-chain 
dehydrogenase/reductase (SDR) superfamilies, with the smaller dihydroflavanol reductase (DFR) 
family also being observed in certain cells. Numerous studies of these protein superfamilies have 
lead to the identification of genes encoding these various reductases and the observation of substrate 
specific trends for these individual genes. The task of identifying individual ketone reductases is 
currently underway. An alternative approach is gene knockout technology. This eliminates the 
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catalytic activities of competing ketone reductases. A number of different strategies may be adopted 
in the genetic manipulation of Baker’s yeast. Foremost amongst these has been the employment of 
gene overexpression and gene knockout techniques. (Figure 18).328 For both approaches, initial 
identification of the individual yeast genes encoding the desired reductases is required to allow the 
production of genetically altered Baker’s yeast strains which produce the targeted product in high 
enantiomeric excess. Gene knockout technology offers an alternative approach to eliminating the 
catalytic activities of competing ketone reductases, provided that their identities are known.328 
Sih et al. pioneered this work in order to improve the enantioselectivity of reduction of a β-keto 
ester; the fatty acid synthase deficient strain led to a dramatic increase in enantioselectivity and 
altered stereospecificity (Scheme 21).329  
 
 
 
Scheme 21. Ketone reductions by wild type and fatty acid synthase deficient (FAS-) Baker’s yeast. 
 
 
Scheme 22 
 
Later, Stewart et al. created a strain of S. cerevisiae that overexpresses cyclohexanone 
monooxygenase (CHMO) so that the whole yeast cells could be used as the biocatalytic oxidant for 
a variety of ketones.330 The stereoselectivities of Baker’s yeast catalysed reductions were 
significantly improved by Kayser et al. by employing recombinant DNA techniques, and rational 
design of the engineered strains. This genetic engineering approach requires the identification of the 
genes encoding each enzyme. The undesirable yeast reductases are subsequently disabled by gene 
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knockout technology while overproducing those reductase enzymes with desirable 
stereoselectivities. The aforementioned methodology was employed to improve the selectivity of β-
keto ester reductions (Scheme 22), the synthesis of novel optically pure β-lactams, and sulfur 
oxidations (Scheme 22).331-333  
 
8. Ketoreductases  
 
8.1. Introduction 
Traditional methods of biocatalytic carbonyl reduction, as discussed above, have been achieved by 
employment of Baker’s yeast as a whole cell catalytic system due to its inexpensive and convenient 
nature. However, as mentioned in Section 7, multiple products may be achieved due to the presence 
of multiple oxidoreductases contained in Baker’s yeast cells. However, ketoreductases, an abundant 
group of oxidoreductase, are present in various bacteria, yeast, and fungi,335,336 and commonly 
participate in many biological processes in all living organisms.337 Enzymatic reductions using a 
purified reductase usually possess high stereoselectivity and eliminate problems with compound 
toxicity associated with viable cells.338 When Stewart et al. examined the genome of Baker’s yeast 
the results indicated the potential for 50 ketoreductases of which 19 were over expressed, isolated, 
and studied.339 The novel isolated ketoreductases reduced a wide range of ketones and produced 
both enantiomers of most products depending on the ketoreductase employed (Figure 19).339  
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Extending this technology to the entire genetic database allowed the commercialisation of larger 
collections of ketoreductase enzymes and enabled the rapid production of large quantities of 
enzyme on demand.339 A further advantage of ketoreductase technology is the rapidity by which 
these screens can be performed.339 An overview of the latest achievements in the field of 
asymmetric ketoreductase-mediated carbonyl reductions can be found in recent reviews.29,66,327,340-
342
 
 
8.2. Cofactor recycling systems 
All ketoreductase biocatalysis require a hydride source in either the form of nicotinamide adenine 
dinucleotide (NADH) or nicotinamide adenine dinucleotide phosphate (NADPH); due to the high 
associated costs of these cofactors it is not practically feasible to use them stoichiometrically. 
Therefore, cofactor recycling systems have been developed in order to recycle the hydride source by 
oxidising the NAD(P)+ back to NAD(P)H and drive the reaction to completion. Some commonly 
used recycling systems are depicted in Figure 20.29  
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Glucose dehydrogenase (GDH), formate dehydrogenase (FDH), phosphite dehydrogenase 
(PDH) are second enzymes added to the process in a coupled enzyme approach.336 GDH is 
commonly the preferred recycling system due to its high stability and activity; furthermore, it 
recycles both NAD+ and NADP+. However, due to the formation of gluconic acid (Figure 20), in 
order to prevent enzyme denaturation, neutralisation of the reaction media with the addition of base 
is required. In addition, by monitoring the amount of base added, facile determination of reaction 
completion is feasible. 
Researchers at Merck developed an efficient asymmetric enzymatic reduction of 4,4-
dimethoxytetrahydro-2H-pyranone 19 which provides the enantiopure (R)-hydroxyketal 20 an 
important chiral precursor for a pharmaceutical intermediate, in high yield including an in situ 
NADPH-cofactor regeneration system using glucose dehydrogenase. The optimised two-enzyme 
process was demonstrated successfully at 80 kg pilot-plant scale (Scheme 23).343 
 
 
 
Scheme 23 
 
Formate dehydrogenase is typically less stable than GDH and only used for the regeneration of 
NAD+. FDH also requires pH adjustment with acid, which is attractive for base labile compounds. 
FDH has been shown by Moore et al. to produce (S)-3,5-bis(trifluoromethyl)phenylethanol 22, a 
pharmaceutically important alcohol intermediate for the synthesis of NK-1 receptor antagonists, via 
asymmetric enzymatic ketone reduction. The isolated enzyme alcohol dehydrogenase from 
Rhodococcus erythropolis reduced the poorly water soluble substrate 21 with excellent 
enantiomeric excess (>99.9 %) and conversion (>98 %) on a lab scale (Scheme 24). However, when 
this transformation was scaled to pilot plant scale, glucose dehydrogenase was employed as the 
cofactor regeneration system. GDH exhibited increased stability to reaction conditions, and use of 
this enzyme also allowed access to both enantiomers of 3,5-bis(trifluoromethyl)phenylethanol 22 in 
excellent enantiopurity by simple switching of a ketoreductase, which was not possible with 
formate dehydrogenase.344 Phosphite dehydrogenase is a novel technology in cofactor recycling; it 
simply converts the reaction buffer from phosphite to phosphate with no significant change in pH 
which is attractive for pH sensitive compounds.345,346  
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Scheme 24 
 
The final example of cofactor recycling discussed here is a substrate coupled approach, this method 
takes advantage of the fact that the ketoreductase not only reduces the ketone of interest, but will 
also oxidise an alcohol such as isopropanol.  
 
 
 
Scheme 25 
 
This system requires a large molar excess of alcohol relative to the ketone. A principal advantage of 
this method is that no pH adjustment is required and the acetone byproduct is easy to remove. 
Savile et al.347 developed an efficient dynamic kinetic resolution protocol employing isopropanol as 
cofactor for the generation of (R)-2-methylpentanol (Scheme 25). The ketoreductase enzyme is the 
sole enzyme employed in the catalytic cycle.  
 
FDH 
Reviews and Accounts  ARKIVOC 2012 (i) 321-382 
Page 366 ©ARKAT-USA, Inc. 
 
 
Scheme 26. Reproduced from reference 343. 
 
This makes process economics quite favourable, since a second enzyme is not required to 
regenerate the cofactor. A purification and isolation method for separating the product from the 
unreacted substrate was also developed. The process has been successfully scaled to produce 100 kg 
of material suitable for use in the production of an API.347 
 
Other, more environmentally benign methods to regenerate NAD(P)H include photochemical 
methods which utilise light energy, by the use of a cyanobacterium, a photosynthetic biocatalyst.348-
351
 Using biocatalysts, the reduction of acetophenone derivatives was investigated and was found to 
occur more effectively under illumination than in the dark. The light energy harvested by the 
cyanobacterium is converted into chemical energy in the form of NADPH through an electron 
transfer system, and consequently, the chemical energy (NADPH) is used to reduce the substrate to 
the chiral alcohol (96 – >99% e.e), (Scheme 26).348-352 Electrochemical methods have also been 
reported.28,350  
 
8.3. Examples of ketoreductase-mediated enantioenriched alcohol synthesis  
Highly enantioselective ketoreductase-mediated resolutions have been performed at a lab scale66,68-
71,340,343,347
 by a number of researchers and these have been reviewed in detail.29,340,353 The 
availability of commercial ketoreductase kits has led to widespread screening of these isolated 
enzymes by chemists (Figure 19 and 21).354 
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Figure 21 
 
Furthermore, over the past 2–3 years ketoreductase technology has been routinely employed 
for the commercial synthesis of chiral alcohols, and are now the preferred catalysts for the synthesis 
of chiral alcohols via ketone reduction.340 Examples of enantioenriched alcohols generated by 
ketoreductase-mediated reduction on an industrial scale and their application are illustrated in 
Figure 22. 
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Figure 22 
 
Two kinds of novel enoate reductases were isolated from Baker’s yeast by Kawai et al. 
which led to nitroalkane enantiopurities of >98% e.e (Scheme 27).334 Deuterium labelling studies 
were carried out and it was concluded that the yeast-mediated reduction of the nitroalkene proceeds 
in two stages: a reversible non stereoselective protonation of the α-carbon followed by a 
stereoselective addition of a hydride from a enzyme at the β-position.334 
 
 
 
Scheme 27 
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